Dr Daniel Ajzensztejn

  • FRCR, MRCP, DPhil (PhD), MSc Oncology, BSc Pharmacology, MBBS
  • Consultant Clinical Oncologist


Special clinical interest in lung cancer, lung malignancies, skin cancer, Stereotactic Ablative Body Radiotherapy, SABR, IMRT, Conformal Radiotherapy, Mesothelioma, Respiratory Medicine

Dr Ajzensztejn undertook a DPhil (PhD) at Oxford University where his research focused on ways to use the body’s own immune system to fight cancer. He continues to be involved in clinical research and is the principle investigator for a number of clinical trials.

He is dedicated to providing the best possible care for his patients and is actively involved in research and learning new techniques and treatment modalities for his patients.


Radiotherapy, SABR, Chemotherapy, concurrent and sequential chemoradiotherapy, immunotherapy, palliative radiotherapy, radical radiotherapy, adjuvant treatments.

NHS Hospital /affiliated hospitals / current post

University Hospitals Oxford

Research interests

Harnessing the immune system to reject cancers through genetic modifications of tumour cells. Combining immunotherapy with radiotherapy.